@StacyALawrence

Business journalist

 Bay Area
Joined March 2012
  • Tweets1.5K
  • Following0
  • Followers1.2K
27Media
Novo Nordisk kills oral insulin, rejigs R&D to address U.S. payers: ow.ly/kXi6305Hp2D $NVO @StacyALawrence
6
5
Ex-Moderna CSO resurfaces at PureTech after abrupt departure: ow.ly/rPZq305opEs @StacyALawrence
1
3
1
Roche highlights I/O combos, as it drops solo development of vanucizumab: ow.ly/5pWL305opyK $RHHBY @StacyALawrence
3
1
J&J backs neuro startup BlackThorn in $40M Series A: ow.ly/EdDx305naj0 $JNJ @StacyALawrence
4
2
Small cap Rigel drops on PhIII failure for lead fostamatinib: ow.ly/q9s4305mVMb $RIGL @StacyALawrence
1
1
Novartis invests, partners with Y Combinator grad in lysosomal storage disorders: ow.ly/PLMb305macq $NVS @StacyALawrence

Novartis invests, partners with Y Combinator grad in lysosomal storage disorders

Novartis ($NVS) teed up its second discovery deal of the day with an investment and partnership with Perlara PBC to discover and develop treatments for lysosomal storage disorders using CRISPR-engi |...

fiercebiotech.com
6
1
6
Celgene partners to develop ResearchKit app for observational study: ow.ly/47qB305k03D $AAPL $CELG @StacyALawrence
3
1
J&J eyes immuno-oncology with 15 R&D assets: ow.ly/jBPu305jZZs @StacyALawrence $JNJ
9
2
AstraZeneca backs ADC in $105M to support 6 clinical oncology candidates: ow.ly/SRTQ305irjN $AZN @StacyALawrence

AstraZeneca backs ADC in $105M to support 6 clinical oncology candidates

AstraZeneca ($AZN) first bought into ADC Therapeutics as part of a 2013 financing. | AstraZeneca first bought into ADC Therapeutics in 2013. Now, it’s upped the ante by participating in a $105...

fiercebiotech.com
3
1
Medicines Co. up on expectations of a twice-yearly anti-PCSK9: ow.ly/TDJS305iaIr $MDCO @StacyALawrence
2
1
2
Stacy Lawrence retweeted
FierceBiotech
@FierceBiotech7 Oct 2016
Clovis reveals ovarian cancer data underlying upcoming FDA review: ow.ly/42tc304X98F $CLVS @StacyALawrence

Clovis reveals ovarian cancer data underlying upcoming FDA review

Clovis Oncology ($CLVS) is set for an FDA review date of February 23 for lead candidate rucaparib. | The company has now revealed the data upon which its rucaparib NDA is based at the ongoing...

fiercebiotech.com
4
2
Stacy Lawrence retweeted
FierceBiotech
@FierceBiotech6 Oct 2016
Merck, NewLink nab up to $76M BARDA contract to back Ebola vaccine: ow.ly/LuH7304UjSO $MRK $NLNK @StacyALawrence
1
1
3
Stacy Lawrence retweeted
FierceBiotech
@FierceBiotech3 Oct 2016
A pair of biotech IPOs line up: Myovant and Ra Pharma: ow.ly/Pv5o304NI47 by @StacyALawrence
2
1
Stacy Lawrence retweeted
FierceBiotech
@FierceBiotech3 Oct 2016
Fidelity backs rare disease startup with $48M to get pivotal data: ow.ly/8KFQ304NyaC via @StacyALawrence

Fidelity backs rare disease startup with $48M to get pivotal data

Specialty pharma spinout Castle Creek Pharmaceuticals has raised its first institutional round of $48 million entirely from active biotech crossover investor Fidelity Management and Research Compan |...

fiercebiotech.com
7
3
Microcap BioLineRx in-licenses a second NASH candidate under Novartis deal - fiercebiotech.com/biotech/mi…

Microcap BioLineRx in-licenses a second NASH candidate under Novartis deal

Israeli biotech BioLineRx ($BLRX) was up about 25% in early trading on news that it has done a second in-licensing deal for a nonalcoholic steatohepatitis (NASH) candidate under a strategic collabo |...

fiercebiotech.com
1
1
Intrexon partners with a pair of its fund portfolio startups - fiercebiotech.com/biotech/in…

Intrexon partners with a pair of its fund portfolio startups

Intrexon ($XON) spearheaded a $245 million fund in January that’s aimed at investing in startups using its technology. | Intrexon has done deals with two of the portfolio companies from a fund...

fiercebiotech.com
4
1
4
German next-gen checkpoint inhibitor startup reels in €40M: ow.ly/niRy304rTNw @StacyALawrence
6
4
Investors go bargain shopping as Novan IPO prices low, climbs high: ow.ly/TWRG304rOsL @StacyALawrence

Investors go bargain shopping as Novan IPO prices low, climbs high

Nitric oxide dermatology player Novan nabbed a nice share price pop on its first day of trading; after the first few hours, it had gained about 55%, which may bode well for other

fiercebiotech.com
2
2
Moderna to plough $110M into manufacturing build-out: ow.ly/FZxU304pZeV @StacyALawrence
5
2
J&J builds on Geron partnership despite ongoing setbacks: ow.ly/8i2N304nVRk $JNJ $GERN @StacyALawrence
1
3
1
Load more